Group 1 - The integration of AI in healthcare is accelerating drug development, enhancing clinical precision, and driving innovation in the medical industry, providing stronger technological support for public health [1][2] - The AI platform "AI Kongming" has been launched, offering free access to databases related to global health challenges, significantly improving candidate molecule hit rates and optimization efficiency by several times compared to traditional processes [1][2] - AI technologies are increasingly applied across various medical fields, including drug development, medical imaging, disease diagnosis, and health monitoring, showcasing their versatility and potential impact [2][3] Group 2 - Major pharmaceutical companies like Shijiazhuang Pharmaceutical Group and Hengrui Medicine are establishing AI research departments to accelerate drug target discovery and clinical trial processes [3][4] - The establishment of innovation platforms, such as the one in Suzhou Industrial Park, aims to facilitate the transformation of medical and engineering innovations, breaking down barriers between data, disciplines, and institutions [4][5] - National policies are being introduced to promote the integration of new information technologies with the pharmaceutical industry, enhancing the application of AI in clinical settings [4][5]

Market Performance - The Hang Seng Technology Index increased by 0.09%, while the Hang Seng Index rose by 0.03% [1] - The Hong Kong Technology ETF (159751) saw a gain of 3.9%, and the Hang Seng Hong Kong Stock Connect ETF (159318) increased by 2.42% [1] Sector Performance - The construction products and life sciences tools sectors showed the highest gains [1] - The leisure equipment and supplies, as well as the automotive sectors, experienced the largest declines [1] Individual Stock Performance - Kuaishou-W surged by 11.09%, and Kelun-B rose by 7.84% [1] - Other notable gainers included Innovent Biologics (6.09%), Beike-W (5.43%), New China Life Insurance (5.34%), BeiGene (5.31%), Chow Tai Fook (5.13%), China Resources Land (5.05%), CSPC Pharmaceutical Group (4.83%), PICC Group (4.57%), Hansoh Pharmaceutical (4.5%), and China Pacific Insurance (4.03%) [1] - In contrast, Innovent Biologics saw a decline of 9.42%, and Global New Material International dropped by 12.6% [1] - Nanjing Panda Electronics experienced a significant increase of 39.75%, while Micron Brain Science rose by 19.73% [1]

Core Viewpoint - Daiwa has released a report recommending specific pharmaceutical stocks, highlighting the preference for Innovent Biologics (01801) and Hengrui Medicine (600276.SH) while maintaining a "sell" rating on CSPC Pharmaceutical Group (01093) [1] Group 1: Stock Recommendations - Innovent Biologics' target price has been raised from HKD 95 to HKD 112 [1] - Hengrui Medicine's target price remains at RMB 80 [1] - CSPC Pharmaceutical Group's target price is maintained at HKD 6.6 with a "sell" rating [1] Group 2: Market Outlook - The Chinese biopharmaceutical sector is expected to experience a comprehensive increase in 2025 [1] - For 2026, Daiwa suggests a more selective stock-picking strategy focusing on high-quality targets [1] Group 3: Key Focus Areas for 2026 - Daiwa plans to outline key clinical data release timelines [1] - The report will identify significant stock price catalysts [1] - Key areas of analysis will include PD-(L)1/VEGF, GLP-1, and siRNA [1]

Core Viewpoint - Daiwa has released a report recommending specific pharmaceutical stocks, highlighting Innovent Biologics (01801) and Heng Rui Medicine (600276) as top picks, with target price adjustments and ratings for other companies in the sector [1] Company Recommendations - Innovent Biologics' target price has been raised from HKD 95 to HKD 112 [1] - Heng Rui Medicine's target price remains at RMB 80 [1] - CSPC Pharmaceutical Group (01093) is rated "Sell" with a target price maintained at HKD 6.6 [1] Industry Outlook - The Chinese biopharmaceutical sector is expected to experience a comprehensive increase in 2025 [1] - For 2026, Daiwa suggests a more selective stock-picking strategy focusing on high-quality targets [1] - Key clinical data release timelines and significant stock price catalysts will be outlined for 2026 [1] - Important areas of analysis include PD-(L)1/VEGF, GLP-1, and siRNA [1]

Core Viewpoint - The approval of the inhaled powder formulation of Nintedanib by the National Medical Products Administration of China marks a significant milestone for the company, allowing it to conduct clinical trials for idiopathic pulmonary fibrosis and potentially for other related conditions [1] Company Summary - The stock price of the company increased by 4.13%, reaching HKD 8.83, with a trading volume of HKD 1.153 billion [1] - The approved clinical indication for the product is idiopathic pulmonary fibrosis, with potential applications for systemic sclerosis-related interstitial lung disease and progressive pulmonary fibrosis [1] - The product represents a key achievement of the company's inhalation technology platform, establishing a solid foundation for the development of subsequent inhalation formulations in its pipeline [1]

Core Viewpoint - The approval of the inhaled powder formulation of Nintedanib by the National Medical Products Administration of China marks a significant milestone for the company, allowing it to proceed with clinical trials for idiopathic pulmonary fibrosis and potentially other related conditions [1] Group 1: Product Development - The inhaled formulation of Nintedanib has received approval for clinical trials in China, specifically targeting idiopathic pulmonary fibrosis [1] - The product also shows potential for treating systemic sclerosis-related interstitial lung disease and progressive pulmonary fibrosis [1] - This approval is considered a key achievement for the company's inhalation technology platform, laying a solid foundation for the development of subsequent inhalation formulations [1] Group 2: Market Reaction - Following the announcement, the company's stock price increased by 4.13%, reaching HKD 8.83, with a trading volume of HKD 1.153 billion [1]

Group 1 - The core viewpoint of the report is that the Chinese biopharmaceutical sector experienced a comprehensive increase in 2025, and for 2026, a more selective stock-picking strategy is recommended, focusing on high-quality targets [1] Group 2 - Daiwa's top picks include Innovent Biologics and Hengrui Medicine, with Innovent's target price raised from HKD 95 to HKD 112, while Hengrui's target price remains at HKD 80 [1] - The rating for CanSino Biologics has been downgraded from "Buy" to "Hold," with its target price increased from HKD 100 to HKD 116 [1] - The rating for CSPC Pharmaceutical Group is maintained at "Sell," with a target price of HKD 6.6 [1]

（原标题：港股午评：恒生科技指数跌0.18% 恒生指数跌0.08%） 港股午间收盘，恒生科技指数跌0.18%，恒生指数跌0.08%。个股方面，信达生物涨超6%，百济神州涨超5%，新华保险涨超5%，中国铝业涨超 4%，药明康德、石药集团涨超4%。 ...

Group 1 - The Hang Seng Technology Index decreased by 0.18%, while the Hang Seng Index fell by 0.08% [1] - The Hong Kong Technology ETF (159751) rose by 3.31%, and the Hang Seng Hong Kong Stock Connect ETF (159318) increased by 2.2% [1] - The construction products and electric power sectors showed the highest gains, while the container and packaging, as well as electrical equipment sectors, experienced the largest declines [1] Group 2 - Notable individual stock performances included Kuaishou-WR rising by 9.97%, Kuaishou-W increasing by 9.66%, and Kelun-Bio rising by 7.84% [1] - Other significant gainers included Beike-W (6.72%), Innovent Biologics (6.28%), BeiGene (5.85%), China Resources Land (5.7%), New China Life Insurance (5.07%), Chow Tai Fook (5.05%), China Aluminum (4.27%), WuXi AppTec (4.16%), and CSPC Pharmaceutical Group (4.01%) [1] - On the downside, Global New Material International fell by 8.33%, and InnoCare Pharma dropped by 9.55% [1] - Nanjing Panda Electronics saw a remarkable increase of 44.93%, while Brainstorm Cell Therapeutics-B rose by 19.85% [1]

Core Viewpoint - The approval of the inhalation powder formulation of Nintedanib by the National Medical Products Administration of China marks a significant advancement for the company, as it is the first inhalation formulation approved for clinical trials in China for the treatment of pulmonary fibrosis [1] Company Summary - The stock price of CSPC Pharmaceutical Group (01093) increased by over 4%, reaching a price of HKD 8.81 with a trading volume of HKD 595 million [1] - The inhalation formulation of Nintedanib is a multi-tyrosine kinase inhibitor that can slow the progression of idiopathic pulmonary fibrosis (IPF) [1] - Compared to the oral soft capsule formulation currently on the market, the inhalation product offers significant advantages, including improved lung exposure, better lung function, reduced systemic exposure, and significantly lower gastrointestinal side effects [1] Clinical Research Summary - Preclinical studies indicate that the inhalation formulation can achieve the same therapeutic effect at a dosage of 1/200 of the oral formulation, demonstrating good safety and efficacy [1]